Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout
Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout
-- Research that has redefined the trajectory and true impact of the disease underscores the campaign --
Through a mix of thought-provoking visuals, expert videos and clinical data, the campaign is designed to inform a modern dialogue about the impact of gout. The goal is to specifically advance the understanding of the complex relationship between pain resolution and gout progression, given the unique mechanism that resolves acute pain in gout often results in patients delaying discussions with the physician. The campaign also underscores the reality of the consequences of inadequate management, such as bone erosion, joint damage and other systemic impacts.
Approximately 9.2 million people in
“The concept of gout as a chronic disease is not widely recognized,”
said Professor
Gout Liesillustrates the ways that the presentation of gout can be deceptive, such as how damage can continue after the end of a flare4,5,6,7,8 or the misconception that tophi – urate deposits that look like lumps under the skin – are a cosmetic issue and not a clinical concern6,8-9. Provocative vintage-style posters help demonstrate how gout is much more complex than its apparent presentation, and damage to the bones, joints and tissue can occur even in the absence of pain and other symptoms.4-8
“We believe that a deeper understanding of the biology of gout can lead
to more precise management of the disease,” said
About Horizon
Horizon is focused on researching, developing and commercializing
medicines that address critical needs for people impacted by rare and
rheumatic diseases. Our pipeline is purposeful: we apply scientific
expertise and courage to bring clinically meaningful therapies to
patients. We believe science and compassion must work together to
transform lives. For more information on how we go to incredible lengths
to impact lives, please visit www.horizontherapeutics.com,
follow us @HorizonNews on
Twitter, like us on
1 Chen-Xu M, Yokose C, Pillinger M, Choi HK. Contemporary
Prevalence of Gout and Hyperuricemia in
2Treatments
for Chronic Gout.
3 Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Annals of the Rheumatic Diseases 2012;71:1765-1770.
4 Perez-Ruiz F, et al.
5 Puig JG, et al. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):592-595.
6 Schett G, et al. RMD Open. 2015;1(suppl 1):e000046.
7 Rada B. J Immunol Res. 2017;2017:2896380.
8 McQueen FM, et al. Rheumatol Oxf Engl. 2014;53(1):95-103.
9 Dalbeth N, et al. Ann Rheum Dis. 2009;68(8):1290-1295.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005188/en/
Source:
U.S. Media Contact:
Amanda Phraner
Associate
Director, Public Relations and Social Media
media@horizontherapeutics.com
Ireland
Media Contact:
Gordon MRM
Ray Gordon
ray@gordonmrm.ie